skip to main content
Idioma:
Refinado por: data de publicação: 2011Até2018 remover Base de dados/Biblioteca: ClinicalKey remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Raal, Frederick J, Prof ; Stein, Evan A, Prof ; Dufour, Robert, MD ; Turner, Traci, MD ; Civeira, Fernando, MD ; Burgess, Lesley, Prof ; Langslet, Gisle, MD ; Scott, Russell, Prof ; Olsson, Anders G, Prof ; Sullivan, David, MD ; Hovingh, G Kees, MD ; Cariou, Bertrand, MD ; Gouni-Berthold, Ioanna, MD ; Somaratne, Ransi, MD ; Bridges, Ian, MSc ; Scott, Rob, MD ; Wasserman, Scott M, MD ; Gaudet, Daniel, Prof

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA
APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA
Material Type:
Artigo 		Adicionar ao Meu Espaço

APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA

Claude Tardif, Jean ; McGowan, Mary ; Ceska, Richard ; Burgess, Lesley J ; Soran, Handrean ; Gouni-Berthold, Ioanna ; Wagener, Gilbert ; Chasan-Taber, Scott

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E492-E492 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
3
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Garber, Alan J, Dr, Prof ; King, Allen B, MD ; Prato, Stefano Del, Prof ; Sreenan, Seamus, MD ; Balci, Mustafa K, MD ; Muñoz-Torres, Manuel, Prof ; Rosenstock, Julio, Prof ; Endahl, Lars A, PhD ; Francisco, Ann Marie Ocampo, MD ; Hollander, Priscilla, MD

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia
Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia

Tardif, Jean-Claude, MD ; Ceska, Richard, MD ; Burgess, Lesley, MD ; Soran, Handrean, MB, ChB, MRCP ; Gouni-Berthold, Ionna, MD ; Wagener, Gilbert, MD ; Chasan-Taber, Scott, PhD ; McGowan, Mary, MD

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.219-220 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
Nanotopography controls cell cycle changes involved with skeletal stem cell self-renewal and multipotency
Nanotopography controls cell cycle changes involved with skeletal stem cell self-renewal and multipotency
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nanotopography controls cell cycle changes involved with skeletal stem cell self-renewal and multipotency

Lee, Louisa C.Y ; Gadegaard, Nikolaj ; de Andrés, María C ; Turner, Lesley-Anne ; Burgess, Karl V ; Yarwood, Stephen J ; Wells, Julia ; Salmeron-Sanchez, Manuel ; Dominic Meek, R.M ; Oreffo, Richard O.C ; Dalby, Matthew J

Biomaterials, 2017-02, Vol.116, p.10-20 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures
ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures
Material Type:
Artigo 		Adicionar ao Meu Espaço

ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures

Peterson, Eric D., MD, MPH, FACC, FAHA ; Ho, P. Michael, MD, PhD, FACC, FAHA ; Barton, Mary, MD, MPP ; Beam, Craig ; Burgess, L. Hayley, PharmD ; Casey, Donald E., MD, MPH, MBA, FACP, FAHA ; Drozda, Joseph P., MD, FACC ; Fonarow, Gregg C., MD, FACC, FAHA ; Goff, David, MD, PhD, FAHA, FACP ; Grady, Kathleen L., PhD, APN, FAHA, FAAN ; King, Dana E., MD, MS, FAAFP ; King, Marjorie L., MD, MAACVPR, FACC ; Masoudi, Frederick A., MD, MSPH, FACC, FAHA ; Nielsen, David R., MD, FACS ; Stanko, Stephen, MBA

Journal of the American College of Cardiology, 2014-11, Vol.64 (20), p.2133-2145 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
7
ACC/AHA/AACVPR/AAFP/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
ACC/AHA/AACVPR/AAFP/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Material Type:
Artigo 		Adicionar ao Meu Espaço

ACC/AHA/AACVPR/AAFP/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures

Peterson, Eric D ; Ho, P Michael ; Barton, Mary ; Beam, Craig ; Burgess, L Hayley ; Casey, Jr, Donald E ; Drozda, Jr, Joseph P ; Fonarow, Gregg C ; Goff, Jr, David ; Grady, Kathleen L ; King, Dana E ; King, Marjorie L ; Masoudi, Frederick A ; Nielsen, David R ; Stanko, Stephen

Journal of the American College of Cardiology, 2014, Vol.64 (20), p.2133-2145 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.